"Accelerating Innovation for Global Health"

Dr. Brian Doehle is a Senior Program Officer on the Accelerator Team, within the Global Health division at the Gates Foundation. His career has been dedicated to the development of therapies for those experiencing viral and inflammatory diseases, including HIV, HCV, HBV, Influenza, SARS-CoV-2 and autoimmune disease. Prior to re-joining the Gates Foundation in 2024, he held various leadership positions in the biotech companies Vir (VP Biomarkers) and Gilead Sciences, where he worked on the development and on market support of treatments for HCV (Sovaldi®, Harvoni®, Epclusa®, and Vosevi®), curative treatments for HIV, and a variety of inflammatory and autoimmune indications. Additionally, he supported BARDA’s Project Next Gen, working to develop next generation therapies for the treatment of COVID-19. From 2019-2021 he worked at the Bill & Melinda Gates Foundation on the HIV Frontiers program, investing in novel technologies, research, and biomarker development focused on bringing curative therapies to resource limited parts of the world. Dr. Doehle obtained a B.S.in Biological Sciences and M.S. in Microbiology from Ohio University, a Ph.D. in Molecular Genetics and Microbiology from Duke University, and postdoctoral training at the University of Washington in innate immunology and viral sensing.